Positive allosteric modulators (PAMs) of the M<sub>1</sub> subtype of muscarinic acetylcholine receptor have attracted intense interest as an exciting new approach for improving the cognitive deficits in schizophrenia and Alzheimer’s disease. Recent evidence suggests that the presence of intrinsic agonist activity of some M<sub>1</sub> PAMs may reduce efficacy and contribute to adverse effect liability. However, the M<sub>1</sub> PAM PF-06827443 was reported to have only weak agonist activity at human M<sub>1</sub> receptors but produced M<sub>1</sub>-dependent adverse effects. We now report that PF-06827443 is an allosteric agonist in cell lines expressing rat, dog, and human M<sub>1</sub> and use of inducible cell lines shows that agonist...
The realization of the therapeutic potential of targeting the M1 muscarinic acetylcholine receptor (...
Subtype-selective antagonists for muscarinic acetylcholine receptors (mAChRs) have long been elusive...
The current frontline symptomatic treatment for Alzheimer's disease (AD) is whole-body upregulation ...
Both historical clinical and recent preclinical data suggest that the M<sub>1</sub> muscarinic acety...
Positive allosteric modulators (PAMs) that target the M1 muscarinic acetylcholine (ACh) receptor (M1...
Selective activation of the M<sub>1</sub> subtype of muscarinic acetylcholine receptor, via positive...
Positive allosteric modulators (PAMs) that target the M1 muscarinic acetylcholine (ACh) receptor (M1...
We previously developed orthosteric M1 muscarinic agonists (e.g. AF102B, AF267B and AF292), which ac...
ABSTRACT Alzheimer's disease and schizophrenia are characterized by expression of psychotic, af...
ABSTRACT: Positive allosteric modulators (PAMs) of the M4 muscarinic acetylcholine receptor (mAChR) ...
Positive allosteric modulators (PAMs) of metabotropic glutamate re-ceptor subtype5 (mGlu5) haveemerg...
Muscarinic acetylcholine receptors (mAChRs), specifically M1 and M4 subtypes, provide viable targets...
The current frontline symptomatic treatment for Alzheimer's disease (AD) is whole-body upregulation ...
Treatments for cognitive deficits associated with CNS disorders such as Alzheimer's disease (AD) and...
The realization of the therapeutic potential of targeting the M1 muscarinic acetylcholine receptor (...
The realization of the therapeutic potential of targeting the M1 muscarinic acetylcholine receptor (...
Subtype-selective antagonists for muscarinic acetylcholine receptors (mAChRs) have long been elusive...
The current frontline symptomatic treatment for Alzheimer's disease (AD) is whole-body upregulation ...
Both historical clinical and recent preclinical data suggest that the M<sub>1</sub> muscarinic acety...
Positive allosteric modulators (PAMs) that target the M1 muscarinic acetylcholine (ACh) receptor (M1...
Selective activation of the M<sub>1</sub> subtype of muscarinic acetylcholine receptor, via positive...
Positive allosteric modulators (PAMs) that target the M1 muscarinic acetylcholine (ACh) receptor (M1...
We previously developed orthosteric M1 muscarinic agonists (e.g. AF102B, AF267B and AF292), which ac...
ABSTRACT Alzheimer's disease and schizophrenia are characterized by expression of psychotic, af...
ABSTRACT: Positive allosteric modulators (PAMs) of the M4 muscarinic acetylcholine receptor (mAChR) ...
Positive allosteric modulators (PAMs) of metabotropic glutamate re-ceptor subtype5 (mGlu5) haveemerg...
Muscarinic acetylcholine receptors (mAChRs), specifically M1 and M4 subtypes, provide viable targets...
The current frontline symptomatic treatment for Alzheimer's disease (AD) is whole-body upregulation ...
Treatments for cognitive deficits associated with CNS disorders such as Alzheimer's disease (AD) and...
The realization of the therapeutic potential of targeting the M1 muscarinic acetylcholine receptor (...
The realization of the therapeutic potential of targeting the M1 muscarinic acetylcholine receptor (...
Subtype-selective antagonists for muscarinic acetylcholine receptors (mAChRs) have long been elusive...
The current frontline symptomatic treatment for Alzheimer's disease (AD) is whole-body upregulation ...